Novavax (NVAX) EBIT Margin (2010 - 2026)
Novavax's (NVAX) quarterly EBIT Margin came in at 11.06% in Q1 2026, down 8839.0% year-on-year from 0.13% in Q1 2025, and down 214.36% quarter-over-quarter from 9.67% in Q4 2025.
Novavax (NVAX) EBIT Margin (2010 - 2026) Analysis & Trends
Novavax's EBIT Margin history runs 17 years deep, the most recent figure standing at 11.06% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 8839.0% year-over-year to 11.06% in Q1 2026; TTM through Mar 2026 was 14.69%, a 4747.0% decrease from a year earlier, with the FY2025 full-year figure at 40.3%, up 7679.0% from the prior year.
- EBIT Margin slipped to 11.06% in Q1 2026 per NVAX's latest filing, from 9.67% in the prior quarter.
- Across five years, EBIT Margin topped out at 77.33% in Q1 2025 and bottomed at 386.37% in Q1 2023.
- The 5-year median for EBIT Margin is 63.01% (2023), against an average of 80.04%.
- Across the five-year window, EBIT Margin surged 30304 bps in 2022 and plunged 41610 bps in 2023, its largest moves.
- Year by year, EBIT Margin stood at 68.24% in 2022, then increased by 8 bps to 63.01% in 2023, then slumped by 136 bps to 148.43% in 2024, then soared by 107 bps to 9.67% in 2025, then sank by 214 bps to 11.06% in 2026.
- Per Business Quant, the three latest NVAX EBIT Margin figures stand at 11.06% (Q1 2026), 9.67% (Q4 2025), and 252.7% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn | -11.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.06% |
| Dec 31, 2025 | 9.67% |
| Sep 30, 2025 | -252.70% |
| Jun 30, 2025 | 57.75% |
| Mar 31, 2025 | 77.33% |
| Dec 31, 2024 | -148.43% |
| Sep 30, 2024 | -158.58% |
| Jun 30, 2024 | 38.75% |
| Mar 31, 2024 | -154.31% |
| Dec 31, 2023 | -63.01% |
| Sep 30, 2023 | -67.19% |
| Jun 30, 2023 | 13.07% |
| Mar 31, 2023 | -386.37% |
| Dec 31, 2022 | -68.24% |
| Sep 30, 2022 | -17.31% |
| Jun 30, 2022 | -259.76% |
| Mar 31, 2022 | 29.73% |
| Dec 31, 2021 | -371.27% |
| Sep 30, 2021 | -171.74% |
| Jun 30, 2021 | -116.04% |